TPDB

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

TPDB ID TPDB92389

Peptide_Name

[I11F-G18K]cT1

Activity

Antibacterial Anticancer Hemolysis Toxicity

Activity_category_statistics

Anti-infective peptides Cancer-related peptides Toxicity and safety peptides

Database_Source

Peptipedia CancerPPD 2.0 PD_Hemolysis

Sequence_Type

standard

Has_Modification No

Description A 18-aa standard natural multi-activity (Antibacterial, Anticancer, Hemolysis, and other sources) peptide sequence curated from Peptipedia, CancerPPD 2.0, and PD_Hemolysis, with an available 3D structural model.

Modification

C-terminal: Cyclized N-terminal: Cyclized

Sequence

KWCFRVCYRGFCYRRCRK

FASTA

>TPDB92389|Antibacterial;Anticancer;Hemolysis;Toxicity|length=18
KWCFRVCYRGFCYRRCRK

Formula C108H164N36O21S4

Absent Amino Acids ANDEQHILMPST

Common Amino Acids R

Mass 2430.96

PI 10.36

Basic Residues 7

Acidic Residues 0

Hydrophobic Residues 6

Net Charge +7

Boman Index -0.84

Hydrophobicity -0.800

Aliphatic Index 16.11

Half Life

Mammalian: 1.3 hour Yeast: 3 min E.coli: 2 min

Extinction Coefficient Cystines 8730

Absorbance 280nm 359.12

Polar Residues 6

number

0

A

5

R

0

N

0

D

4

C

0

E

0

Q

1

G

0

H

0

I

0

L

2

K

0

M

2

F

0

P

0

S

0

T

1

W

2

Y

1

V

Amino Acid Distribution

A: 0 R: 5 N: 0 D: 0 C: 4 E: 0 Q: 0 G: 1 H: 0 I: 0 L: 0 K: 2 M: 0 F: 2 P: 0 S: 0 T: 0 W: 1 Y: 2 V: 1

Length

18

Formula

C108H164N36O21S4

Mass

2430.96

PI

10.36

Net Charge

+7

Boman Index

-0.84

Hydrophobicity

-0.800

C_terminal_Modification

Cyclized

Chirality

L

Linear_or_Cyclic

Cyclic

N_terminal_Modification

Cyclized

Nature

Host Defense Peptide

Origin

Synthetic

Evidence 1 Activity

Activity

Activity Endpoint CC50

Activity Raw

CC50 = 1.3 ± 0.1 µM

Detail Source Activity Anticancer

Activity Measurement 1.3

Target

Cancer Type Skin Cancer

Cell Line MM96L

Tissue Affected Skin

Assay & Model

Assay Resazurin dye assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2019

Other

Source Activity Label	Source Definition
Anticancer	CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.

Evidence 2 Activity

Activity

Activity Endpoint CC50

Activity Raw

CC50 = 3.2 ± 0.1 µM

Detail Source Activity Anticancer

Activity Measurement 3.2

Target

Cancer Type Skin Cancer

Cell Line HT-144

Tissue Affected Skin

Assay & Model

Assay Resazurin dye assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2019

Evidence 3 Activity

Activity

Activity Endpoint CC50

Activity Raw

CC50 = 2.9 ± 0.2 µM

Detail Source Activity Anticancer

Activity Measurement 2.9

Target

Cancer Type Skin Cancer

Cell Line WM164

Tissue Affected Skin

Assay & Model

Assay Resazurin dye assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2019

Evidence 4 Activity

Activity

Activity Endpoint CC50

Activity Raw

CC50 = 1.9 ± 0.1 µM

Detail Source Activity Anticancer

Activity Measurement 1.9

Target

Cancer Type Leukemia Cancer

Cell Line K-562

Tissue Affected Blood

Assay & Model

Assay Resazurin dye assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2019

Evidence 5 Activity

Activity

Activity Endpoint CC50

Activity Raw

CC50 = 5.1 ± 0.3 µM

Detail Source Activity Anticancer

Activity Measurement 5.1

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay Resazurin dye assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2019